An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
A phase 3 trial of Venetoclax in multiple myeloma and non-hodgkin lymphoma, run by AbbVie, active and no longer recruiting.
Overview
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial is a phase 3 interventional study registered as NCT03844048 by AbbVie, with 165 participants enrolled, started 2019-09-06 and due to reach its primary completion in 2027-08. Interventions recorded: Venetoclax. Conditions listed: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
- TrialA Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Shares Venetoclax, Multiple myeloma.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
- TrialA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex)
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Multiple myeloma.
- TrialStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Multiple myeloma.
- TrialA Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- TrialStudy to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Multiple myeloma.